ABSTRACT Background: The influence of prenatal long-chain polyunsaturated fatty acids (LC-PUFAs) and folate on neurologic development remains controversial.
INTRODUCTION
Over the past decades, increasing attention has been given to the need for an adequate supply of long-chain polyunsaturated fatty acids (LC-PUFAs), especially docosahexaenoic acid (DHA), to the developing fetus and the infant. The developing fetus requires fatty acids as a source of energy, as well as for the conformation of membranes, in which they play an important role in maintaining their physical and chemical properties (1, 2) . Approximately 50-60% of human brain dry weight is constituted by lipids; '35% of the lipids are PUFAs and most of them are LC-PUFAs (3) . The growth spurt of the human brain, and hence rapid DHA accretion, takes place from the beginning of the third trimester of gestation to the 18th month of postnatal age (4) . Before birth, DHA is mainly transported to the fetus from the mother across the placenta, and after birth the infant is provided with DHA in the mother's milk (2) .
Studies on postnatal LC-PUFA supplementation have not been able to establish an unequivocal beneficial effect of LC-PUFAsupplemented formulas on neurodevelopment in either term or preterm infants (5, 6) . Observational studies have associated higher maternal fish consumption during pregnancy, as well as higher DHA concentrations in cord blood at birth, with a better neurologic outcome (7) (8) (9) (10) (11) (12) (13) (14) , but very few have followed the children's development later in life. Interventional studies on prenatal supplementation to expectant women have conflicting results. n-3 LC-PUFA supplementation during pregnancy has been related to a better performance on a problem-solving task at 9 mo of age (15) , better eye and hand coordination in the Griffiths Mental Development Scales at 2.5 y of age (16) , and a higher Mental Pro-cessing Composite (MPC) Score in the Kaufman Assessment Battery for Children (K-ABC) at age 4 y (17) . Other interventional studies did not show any association between a child's neurodevelopment and supplementation (18) (19) (20) . These inconclusive results could be attributable to differences in the dosage and timing of supplementation, differences in the control formula, and differences in the methodology used to assess neurologic condition in the children. To our knowledge, only one study has assessed the long-term effects of supplementation (17, 20) .
Umhau et al (21) reported that folate deficiency modifies plasma and tissue fatty acid composition. 5-methyltetrahydrofolate (5-MTHF) provides methyl groups for the methylation of homocysteine to form methionine, which influences fatty acid metabolism (22) . In addition, some studies have reported a positive association between the neurologic development of children and folic acid supplementation or folate status during pregnancy (23) (24) (25) (26) . However, studies on the influence of prenatal folate on neurologic development are scarce and the findings are not consistent. This is a follow-up study of the NUHEAL (Nutraceuticals for a Healthier Life) cohort. The study examines the effects of n23 (omega-3) LC-PUFA and/or 5-MTHF supplementation during brain development (second half of pregnancy and first 6 mo of postnatal life) on long-term neurologic outocome of children at 6.5 y of age.
SUBJECTS AND METHODS

Study design
The study design has been described previously (27) . Briefly, healthy pregnant women attending antenatal care clinics were recruited before the 20th week of pregnancy in 3 different European centers (Ludwig-Maximilians-University of Munich, the University of Granada, and the University of Pécs). Inclusion criteria consisted of apparently healthy pregnant women aged 18-40 y with uncomplicated singleton pregnancies and a body weight between 50 and 92 kg at study entry. The women should not have used fish-oil (FO) supplements since the beginning of pregnancy, or folate and/or vitamin B-12 supplements after the 16th week of gestation. Blockwise randomization was performed through stratification by each center for the allocation of participating women into 4 different supplementation groups. From the 20th week of pregnancy until delivery, the women received one sachet per day with a milk-based supplement (Blemil Plus Matter; Ordesa Laboratories SL, Barcelona, Spain) containing either modified FO providing 500 mg DHA + 150 mg eicosapentaenoic acid (Pronova Biocare, Lysaker, Norway), 400 lg 5-MTHF (BASF, Ludwigshafen, Germany), or both or a placebo, together with vitamins and minerals in amounts meeting the European recommendations for pregnant women in the second half of pregnancy. Neither the participating women nor the study personnel knew the content of the sachets. Detailed information on sociodemographic data was collected in standardized reports at study entry. Information on the course of pregnancy and delivery was also collected at the 20th and 30th week of pregnancy and at delivery. Food-frequency questionnaires were administered at the 20th and 30th week of pregnancy. Maternal blood samples were obtained by venipuncture into EDTA-containing tubes at the 20th and 30th week of pregnancy, as well as at delivery. Cord blood samples were obtained at delivery after clamping of the umbilical cord and before parturition of the placenta, by puncture and aspiration from a long cord segment. After birth, the women were encouraged to breastfeed their infants. Infants requiring supplementation or substitution of breastfeeding were provided with 1 of 2 different formulas. These 2 formulas followed the European legislative standards and were identical in all components, with the exception of the fatty acid composition. Children born from FO-supplemented women received a formula containing 0.5% of total fatty acids as DHA and 0.4% of arachidonic acid (AA), whereas children in the placebo or 5-MTHF groups received a formula virtually free of DHA and AA during the first 6 mo of postnatal life.
Cognitive assessment of the children was performed with the K-ABC at the age of 6.5 y. Potential cofounders were assessed by means of standardized questionnaires containing information on children's health status.
The study protocol was approved by the medical ethics committees of all centers participating in the study. Written informed consent was obtained from all participants at study entry and at follow-up.
Study population
The study described is part of the NUHEAL follow-up project that has been described previously (27) . Two hundred seventy women took part in the study until giving birth; the baseline characteristics of the initial study population have been reported previously (27) . Study participants were approached again and asked to participate in the neurologic assessment of their children at 6.5 y of age and 161 complied with the request (Figure 1 ). There were no differences in the dropout rates between intervention groups. The main reasons for dropping out were relocation (n = 3), loss of contact (n = 74), and unwillingness to continue (n = 30). Four children were born prematurely before the 35th week of pregnancy, one child was born with a congenital left-side anophthalmus, one child developed craniosynostosis, and another was reported to have left-side deafness. These children were excluded from the analyses, which left 154 children. No other illness or disability interfering with normal neurologic development was observed. There were no differences regarding baseline characteristics between followed children from the different intervention groups ( Table 1) . The mean dietary intake of DHA of the participating women was similar in all intervention groups at the 20th and 30th week of pregnancy. The study population did not differ from the not-tested population regarding maternal parity, body mass index, smoking habits, obstetric risk factors, complications at parturition, or perinatal morbidity in any intervention group. There was a higher attrition of children whose fathers had a high educational level in the placebo and FO + 5-MTHF groups [76.9% of children with fathers with general qualification for university entrance in the placebo group and 70.8% in the FO + 5-MTHF group withdrew at 6.5 y follow-up, whereas only 40% of the fathers of followed children in the placebo group and 30.6% in the FO + 5-MTHF group had this qualification (P = 0.003)]. Length of gestation in the 5-MTHF and placebo groups was significantly higher in the group of children continuing in the study than in the group of dropouts (5-MTHF: 38.71 6 1.6 wk compared with 37.63 6 2.6 wk, P = 0.041; placebo: 39.13 6 1.5 wk compared with 38.12 6 2.1 wk, P = 0.024). Birth length in the 5-MTHF group was also higher in the study population taking part in the follow-up (49.22 6 3.5 cm compared with 51.10 6 1.8 cm, P = 0.011). Head circumference at birth in both the placebo and 5-MTHF groups was significantly higher in the groups of children participating in the follow-up (placebo: 33.75 6 2.0 cm compared with 34.85 6 1.3 cm, P = 0.021; 5-MTHF: 33.48 6 2.9 cm compared with 34.74 6 1.4 cm, P = 0.041). There were no differences between tested and not-tested children with respect to paternal educational level, length of gestation, or length and head circumference at birth in the rest of the intervention groups. The mean age at K-ABC assessment was 79.16 6 12.68 mo.
Fatty acid analyses
Blood was centrifuged at 3500 · g for 10 min at room temperature within 2 h. Plasma was thereafter removed and stored at 280°C. The remaining erythrocyte mass was washed in isotonic sodium chloride solution, hemolyzed in distilled water, and kept at 280°C with isopropylic alcohol and butylated hydroxytoluene until further analysis. Lipid extraction from plasma was performed according to the method of Kolarovic and Fournier (28) . Phospholipids were isolated by liquid chromatography with the use of aminopropyl columns (Sep Pak Cartridges; Waters, Milford, MA) (29) . Lipids from erythrocyte were extracted according to the method described by Folch et al (30) and phospholipids were isolated by thin-layer chromatography. The bands were stained with dichlorofluorescein, visualized under ultraviolet light, and scraped for transmethylation. The isolated phospholipids were transesterifed by treatment with methanolic hydrochloric acid (31) .
Analysis of fatty acid methyl esters from plasma phospholipids was performed by gas chromatography with the use of a gas chromatograph (HP5890 Series II; Hewlett-Packard, Palo Alto, CA) with a flame ionization detector. Fatty acid methyl esters were identified by comparison of retention times with those of known standards (27) . The quantification of fatty acid methyl esters from erythrocyte phosphatidylethanolamine and phosphatidylcholine was performed by high-resolution capillary gas-liquid chromatography (model 9001 gas chromatography; Finnigan/Tremetrics, Austin, TX) with split injection, automatic sampler (A200SE; CTC Analytic, Switzerland), and flame ionization detector with a DB-23 cyanopropyl column of 60-m length (J & W Scientific, Folsom, CA). Conditions during the analysis and standards used were recently described elsewhere (32) . For identification of sample peaks we used 2 commercially available fatty acid methyl ester calibration mixtures (Supelco 37 FAME mix and NU-CKECK GLC reference 463) containing the fatty acids measured in the present study. Results were expressed as percentages by weight (wt %) of total detected fatty acids.
Folate analysis
Analysis of plasma folate was carried out by microbiological assay with the use of a chloramphenicol resistant strain of Lactobacillus casei (33) . Inter-and intraassay CVs were ,11%.
Assessment of cognitive function (K-ABC)
The K-ABC test is designed for children between 2.5 and 12.5 y of age to evaluate intelligence and achievement. The test comprises 16 subtests (10 mental processing subtests and 6 achievement subtests), although not all of them are used for every age group. Neurologic findings are summarized with 3 scores: the Sequential Processing Scale, the Simultaneous Processing Scale, and the Achievement Scale (not used in the present study). The Sequential Processing Scale primarily measures short-term memory and consists of subtests that evaluate children's ability to solve problems that require the arrangement of stimuli in sequential order. The Simultaneous Processing Scale examines problem-solving skills that require processing of many stimuli at once. The Sequential and Simultaneous Processing Scales are combined to form the MPC, which is a global measure of the child's cognitive ability and is considered equivalent to the intelligence quotient. Raw scores are transformed into standard scores with a mean of 100 and an SD of 15 and percentile scores (34) .
Statistics
The power calculation showed that the size of the remaining group allowed for a detection of 6.85 (0.7 SD) points of difference in the standard MPC score obtained with the K-ABC at 6.5 y follow-up, with a P value of 0.05 and a statistical power of 80%. Variables were assessed for normality. A 2-factor analysis of variance was used to assess the effects of FO and 5-MTHF and their interaction on maternal and cord DHA, AA, and folate status. When the findings were significant, multiple comparisons with Bonferroni corrections were performed. Regarding the baseline characteristics of the participants, differences between intervention groups for numeric variables were assessed by analysis of variance in the normally distributed variables and the Kruskal-Wallis test in the not normally distributed variables. For categoric variables chi-square tests were applied. To assess the effects of supplementation on the K-ABC scores, Kruskal-Wallis tests were performed.
The percentile scores of the MPC could not be transformed to normality, and were dichotomized (MPC .50th percentile and MPC ,50th percentile). Stepwise logistic regressions were performed with the dichotomized scores as the dependent variable and LC-PUFA and folate concentrations together with confounders as independent variables.
Maternal age, parity, body mass index, hematocrit at the 30th week of pregnancy, and smoking habit during pregnancy, as well as lengthof gestation, gravidity risk factors, delivery complications, and parental educational attainment and work status were taken into account in the statistical analyses. Infant weight, length, and head circumference at birth; Apgar score and perinatal morbidity; sex; and breastfeeding status, as well as body mass index and health status of thechildren at6.5y werealsoincluded.Becauseofthehigh numberof control variables, only those related to the outcome variable at P values ,0.2 were entered as covariables in the analysis.
A P value of 0.05 was considered significant. Statistical analyses were performed with the use of SPSS 15.0 for Windows (SPSS Inc, Chicago, IL). Mean LC-PUFA (wt %) and plasma folate concentrations in maternal and cord blood are shown in Table 2 . Mothers who received FO supplements during the second half of their pregnancy had significantly higher DHA percentages in plasma and erythrocyte phospholipids at delivery than did those who received 5-MTHF alone or placebo (P , 0.001). Likewise, children born from FO-supplemented mothers had significantly higher DHA percentages in cord plasma and erythrocyte phospholipids compared with those born from mothers who were not FO supplemented (P , 0.001). AA concentrations in plasma and erythrocyte phospholipids were similar between intervention groups. Maternal plasma folate concentrations were significantly higher in week 30 of pregnancy and at delivery in the groups receiving 5-MTHF supplements compared with the FO and placebo groups (P , 0.001). There were no differences between groups regarding cord plasma folate concentrations. No interaction was observed between the FO and 5-MTHF supplements.
The AA-to-DHA ratio in maternal plasma phospholipids in the placebo group at the 20th and 30th week of pregnancy, as well as at delivery and in cord blood, was significantly lower in the children taking part in the study than in those who withdrew (20th week: 2.71 6 0.71 compared with 2.12 6 0.59, P = 0.001; 30th week: 2.69 6 0.71 compared with 2.12 6 0.56, P = 0.001; delivery: 2.75 6 0.67 compared with 2.20 6 0.61, P = 0.002; cord blood: 3.34 6 0.78 compared with 2.64 6 0.64, P = 0.001). Folate concentrations were significantly higher in maternal plasma at delivery (10.64 6 8.45 compared with 9.49 6 6.17, P = 0.012), as well as in cord plasma (15.33 6 8.74 compared with 14.80 6 5.45, P , 0.001) in the group of dropouts compared with the group that completed the follow-up.
Cognitive function
There were no significant differences in the K-ABC scores at 6.5 y of age between the 4 intervention groups ( Table 3) . The FO and FO + 5-MTHF groups and the placebo and 5-MTHF groups were similar with respect to their basal clinical and sociodemographic characteristics and LC-PUFA (wt %) in cord blood. We pooled together the groups with and without FO supply to increase the power of the study for detecting differences, but we observed no significant differences. Likewise, we did not find significant differences between intervention groups after pooling together the groups with and without 5-MTHF.
We observed that children with MPC scores above the 50th percentile had mothers with significantly higher DHA percentage concentrations in erythrocyte phosphatidylethanolamine (20th week: 4.09 6 1.85 compared with 5.16 6 1.98, P = 0.035; 30th week: 5.06 6 1.98 compared with 6.42 6 2.25, P = 0.014; delivery: 5.95 6 1.68 compared with 7.85 6 2.58, P , 0.001) and phosphatidylcholine (30th week: 1.52 6 1.09 compared with 2.85 6 1.52, P = 0.001; delivery: 2.09 6 0.92 compared with 3.23 6 1.58, P , 0.001) during the course of pregnancy. There were no significant differences regarding cord blood fatty acid relative concentrations. Regarding maternal plasma folate concentrations at any time in pregnancy and cord plasma folate concentrations at delivery, no statistically significant differences were observed between children with an MPC above the 50th percentile and those with an MPC under the 50th percentile.
Adjustment for confounders in the stepwise logistic regression (Table 4) showed that children whose mothers had higher DHA percentages in erythrocyte phosphatidylethanolamine at delivery were more likely to have an MPC score above the 50th percentile. Likewise, a higher AA:DHA ratio in maternal erythrocyte phosphatidylethanolamine at delivery was associated with MPC scores under the 50th percentile. No influence of maternal or cord folate concentrations on the odds of a child having an MPC above the 50th percentile was observed.
DISCUSSION
Almost all studies conducted to date that have investigated the effects of prenatal n23 LC-PUFA supplementation on neurologic condition have assessed neurologic development early in life. Evidence of the benefits of LC-PUFA supplementation in healthy children at older ages is too limited to allow unequivocal conclusions. Only one of these studies has followed children .4 y old (17, 20) . The current study examines this relation at 6.5 y of age.
Helland et al (17) reported higher scores on the MPC of the K-ABC at 4 y of age in children born to mothers who received cod oil supplements during the second half of pregnancy and 3 months after delivery compared with those whose mothers received corn oil supplements. The fact that we did not find differences could be explained by the differences between studies regarding n23 LC-PUFA supplementation dosage and timing. We supplemented our women with 500 mg DHA daily from the 20th week of pregnancy until delivery, whereas Helland et al (17) provided their study population with a far higher dose of 1183 mg DHA per day from the 18th week of pregnancy until the third month after delivery. DHA concentrations in cord plasma phospholipids in the FO-supplemented group reported in the Norwegian study (63.7 6 26.8 lg/mL) were higher than ours (54.9 6 1.8 lg/mL mean DHA in the FO and FO + 5-MTHF groups). Furthermore, whereas Helland et al (17) reported a mean difference of 21.3 lg/mL between the cod liver oil-and the corn oil-supplemented groups, we showed a difference of only 6.5 6 2.5 lg/mL between the FO-supplemented groups and those who received 5-MTHF or placebo. It appears possible that higher n23 LC-PUFA doses are needed to have a measurable effect on cognitive development. Although the dose of n23 LC-PUFA administered in the current study was high enough to induce a significant increment of DHA percentage concentrations in maternal and cord plasma and erythrocyte phospholipids, the DHA percentage concentrations in cord blood were within the range of normal variability for healthy term infants. Nevertheless, despite the higher DHA concentrations in supplemented groups reported by Helland et al (20) , they observed no differences in the scores of the K-ABC between supplementation groups at the age of 7 y.
Most of the studies detecting significant effects of supplementation on neurologic outcome have been conducted earlier in life. The lack of differences observed in our study could also be due to differences in the tests used to assess neurologic development. Because of the difficulties in the assessment of the cognitive function during infancy, most of the tests used in the (35) and Ghys et al (36) did not establish a significant association between LC-PUFA in umbilical plasma phospholipids at delivery and the cognitive performance in the K-ABC at 4 and 7 y of age in their observational study. However, they showed a positive relation between umbilical plasma DHA and the quality of movements of the Maastricht Motor Test at 7 y in the same study population (37) . LC-PUFA might exert effects on motor function, and therefore the K-ABC may not be suitable to detect such effects. Another possible explanation for our results is that that the effects of supplementation are transient and can be detected only in younger children. Neurologic development is influenced by many factors, such us genetics, social stimulation, diseases, or nutrition, in the first years of life. Thus, the subtle beneficial effects of LC-PUFA supplementation may be overshadowed by factors intervening between infancy and school age that may influence neurologic outcome.
In this study, we did not assess genetic variation between subjects in the activity of endogenous LC-PUFA formation. Recent observations in pregnant women who participated in the Avon Longitudinal Study of Parents and Children (ALSPAC) study indicate that polymorphisms in the gene cluster for fatty acid desaturases 1-3 have a significant effect on blood DHA concentrations (38) . Two fatty acid desaturase 2 polymorphisms were shown to significantly alter the effect of postnatal breastfeeding, which supplies DHA, on the intelligence quotient achieved at age 8 y (39). Therefore, not including assessments of fatty acid desaturases genotype in our study may have reduced the sensitivity and precision of detecting the effects of a dietary DHA supply.
The logistic regression analysis showed that high DHA (wt %) in maternal erythrocyte phosphatidylethanolamine is related to MPC scores above the 50th percentile. Our results are in agreement with those of some other studies that reported a positive association between DHA and neurologic development (7) (8) (9) (10) (11) (12) (13) . The few of them that provided information beyond infancy have controversial results. High maternal consumption of seafood has been reported to be beneficial for children's neurodevelopment (14, 40, 41) . Moreover, higher DHA in cord blood at birth has been associated with better eye-hand coordination in the Griffiths Mental Development Scales at 2.5 y of age (16) and higher quality of movements in the Maastricht Motor Test (37) , as well as lower internalizing problem behavior at age 7 y (42). Helland et al (17, 20) also reported a significant correlation between intelligence scores on the K-ABC at 4 y and DHA concentrations in children's plasma phospholipids 4 wk after delivery, as well as between the intelligence scores at age 7 y and DHA concentration in maternal plasma phospholipids in the 35th week of pregnancy. In contrast, the previously mentioned observational studies did not establish any association between cord blood DHA and intelligence scores on the K-ABC at either age 4 or 7 y (35, 36) . The detected association of cognitive function with DHA in erythrocyte phospholipids but not with plasma phospholipids in our study could indicates that long-term LC-PUFA intake is more beneficial than receiving supplementation alone during pregnancy. Therefore, we speculate that maternal DHA status before the 20th week of gestation may be of importance for the child's outcome.
Studies on the influence of prenatal folate supplementation and subsequent child neurologic development are scarce. To our knowledge, this is the first interventional study to assess the effects of folate supplementation during the second half of pregnancy on neurologic outcome of the offspring. Longitudinal studies have related the use of folic acid supplements during pregnancy to better neurologic development in children up to the age of 4 y (23, 26), which contrasts with our finding of no differences in the MPC between intervention groups. Furthermore, we did not find any association between maternal folate status and neurologic development at weeks 20 and 30 of pregnancy or at delivery. This is in agreement with Tamura et al (43) , who observed no association between maternal plasma or erythrocyte folate concentrations during the second half of pregnancy and the neurodevelopment of children at 5 y of age, but contrasts with the results reported by some other authors who showed an association between maternal dietary intake of folate (25) or folate status during pregnancy (24) and neurologic development of their children. It should be noted that the mean maternal folate concentrations at 30-wk gestation in this study were substantially lower than the cross-sectional data reported by Veena et al (24) at the same pregnancy time point (15.3 lg/L after conversion to equivalent units). The folate concentrations of our supplemented mothers fall within the second-lowest quartile of their study. Given the high attrition in our study, we were able to detect a difference of 4.5 points in the MPC with the remaining sample size at 6.5 y follow-up after pooling together the FO-supplemented and the non-FO-supplemented groups. This is slightly more than the 4.1 points of difference that Helland et al (17) detected in their study. We consider the power of the study high enough to detect clinically relevant differences between groups. Furthermore, we did not see a trend in our data. Therefore, we do not think that a larger sample would have led us to find significant differences. The high attrition could also have induced a bias that may have made it difficult to detect differences. Children with fathers with a high educational level were underrepresented in the placebo and FO + 5-MTHF groups, and those with higher length of gestations, head circumference, and length at birth were overrepresented in the non-FO-supplemented groups (the placebo and 5-MTHF groups). Both parental educational level and birth anthropometric measures have been previously related to cognitive development (35) . However, logistic regression analysis did not show any association between these covariables and intelligence sores in the present study.
Our results do not provide evidence of a beneficial effect of n23 LC-PUFA or 5-MTHF supplementation during the second half of pregnancy and the first months of postnatal life on cognitive performance at 6.5 y of age. Prenatal DHA status seems to have subtle positive effects on neurodevelopment, but further research is needed to assess whether these effects are maintained beyond early childhood. The optimal doses for efficacy at different developmental stages also require consideration.
